Bristol Myers Squibb announced a multi-billion dollar partnership with Chinese drugmaker Hengrui Pharma to co-develop about a dozen drugs, including sending four experimental Bristol drugs to China for early-stage trials. This deal marks a shift as U.S. companies increasingly use China for faster, cheaper early drug development, integrating China into global pharma R&D rather than treating it as a one-off source. The collaboration reflects a broader trend of Western pharma firms leveraging China's capabilities to speed up drug discovery and development, potentially reshaping the global pharmaceutical landscape.
A dividend growth portfolio focusing on Dow Dividend 100 stocks optimizes for payout ratios, EBITDA yield, and dividend growth. EOG Resources, Comcast, and Accenture are top holdings based on a multi-factor scoring system. The portfolio offers a 3.28...
The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising c...
The Schwab U.S. Dividend Equity ETF (SCHD) delivers a higher dividend yield of about 4.1% compared to Vanguard Value ETF's (VTV) 1.9%, while maintaining similar long-term returns. SCHD focuses on 100 dividend-paying, cash-generative companies, offeri...
Hengrui Pharma and Bristol Myers Squibb have entered a strategic global collaboration worth up to $15.2 billion to jointly develop 13 early-stage programs in oncology, hematology, and immunology. The deal includes asset exchanges where BMS gains righ...
The personalized medicine market is projected to grow from USD 524 billion in 2025 to over USD 1 trillion by 2034, fueled by advances in genomics, biomarker diagnostics, and AI-powered data analytics. This growth is driven by rising chronic diseases ...
